WINT — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2025-11-19

• We are a diversified company focused on seeking partnerships and becoming a revenue-generating company through various initiatives. We became the manufacturing sourcing agent for Evofem’s FDA-approved product Phexxi® in March 2025 and signed the manufacturing deal with Zhoake (Hong Kong) Ophthalmolo…

• Our portfolio of product candidates includes istaroxime, a Phase 2 candidate that inhibits the sodium-potassium ATPase and also activates sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, for acute heart failure and/or associated cardiogenic shock; preclinical SERCA2a activators for heart fai…

• Our lead product candidate, istaroxime, is a first-in-class, dual-mechanism agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure, or AHF, and reverse the hypotension and h…

• Our heart failure cardiovascular portfolio also includes next generation SERCA2a activators. One family of compounds has the dual mechanism of action that includes inhibition of the sodium-potassium ATPase as well as activation of SERCA2a. The other family of compounds are considered selective SERCA…

• Our cardiovascular assets and programs are associated with a regional licensed partnership with Lee’s Pharmaceutical (HK) Ltd., or Lee’s (HK), for the development and commercialization of our product candidate, istaroxime, in Greater China. In addition to istaroxime, the agreement also licenses our …

Text removed vs the prior filing · source: 10-Q · 2025-08-19

• We are a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Our portfolio of product candidates includes istaroxime, a Phase 2 candidate that inhibits the sodium-potassium ATPase and also activates sarco endoplasmic reticulum Ca…

• In addition, in January 2025, we launched a new corporate strategy to become a revenue generating biotech company through acquisitions of small companies and their FDA-approved products while the Company continues to progress its cardiovascular and oncology development pipeline. The Company will see…

• On July 16, 2025, we announced our launch of a crypto treasury strategy utilizing the native token of the BNB chain commonly referred to as “BNB,” including a $60 million securities purchase agreement led by Build and Build, Corp. with the potential for up $200 million of total subscriptions. For ad…

• Our lead product candidate, istaroxime, is a first-in-class, dual-mechanism agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure, or AHF, and reverse the hypotension and h…

• Our heart failure cardiovascular portfolio also includes other SERCA2a activators. One family of compounds has the dual mechanism of action that includes inhibition of the sodium-potassium ATPase as well as activation of SERCA2a. The other family of compounds are considered selective SERCA2a activat…

Text added vs the prior filing · source: 10-Q · 2025-11-19

• We do not have sufficient resources available to fund our business beyond December 2025. To increase our cash runway, management plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions…

• however, none of these alternatives are committed at this time. There can be no assurance that we will be successful in obtaining sufficient funding, or that such funding will be available on terms acceptable to us, to fund continuing operations, if at all, or identify and enter into any strategic t…

• Further, under the terms of the various Note Purchase Agreements, we are subject to certain restrictive covenants that may make it difficult to procure additional financing. As a result of these covenants, our ability to respond to changes in business and economic conditions and engage in beneficial…

• On August 19, 2025, we were notified by Nasdaq that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist our common stock from the Nasdaq Capital Market. We began trading publicly on the over-the-counter market (“OTCID”)…

• The delisting of our securities by Nasdaq could adversely affect the trading market for our securities, as price quotations may not be as readily obtainable, which would likely have a material adverse effect on the market price of our securities and the Company’s ability to raise additional capital.

Text removed vs the prior filing · source: 10-Q · 2025-08-19

• We do not have sufficient resources available to fund our business beyond December 2025. To increase our cash runway, management plans to secure additional capital, potentially through a combination of public or private securities offerings, convertible debt financings, and/or strategic transactions…

• Further, under the terms of the Purchase Agreements, we are subject to certain restrictive covenants that may make it difficult to procure additional financing. As a result of these covenants, our ability to respond to changes in business and economic conditions and engage in beneficial transactions…

• In May 2020, we successfully listed our common stock on Nasdaq. However, we can give no assurance that we will be able to satisfy the continued listing requirements of Nasdaq in the future, including but not limited to the corporate governance requirements and the minimum closing bid price requireme…

• Accordingly, unless the Company requested by June 25, 2025, a hearing before a Hearings Panel (the “Panel”), or the Company’s securities would be subject to suspension/delisting. The Company timely requested a hearing before the Panel.

• The hearing request automatically stayed any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. The hearing was held on July 31, 2025. There can be no assurance that the Panel will grant the Company an …

Text added vs the prior filing · source: 10-Q · 2025-11-19

• Termination of the Letter of Intent with Titan Environmental Services, Inc.

• On November 11, 2025, the Company entered into a Letter Agreement (the “Agreement”) with Titan Environmental Services, Inc (“TESI”) in connection with the previously disclosed Letter of Intent (“LOI”) from June 6, 2025. The LOI contemplated that the Company would acquire all of the issued and outsta…

• The Letter Agreement releases The Company and TESI from any and all reciprocal surviving obligations under the LOI and establishes an arrangement for the return of the $7.5 million advance in the form of a combination of cash and securities.

• Pursuant to the Letter Agreement, the Outstanding Amount shall be converted into a number of shares of the equity of TESI or the of the surviving entity in any consolidation, merger or reorganization with TESI (the “Transaction”) to be agreed upon by the TESI and the Company prior to the closing of …

• The parties also agree that the execution of the Letter Agreement settles all actual and potential obligations of TESI towards the Company and upon payment of the Equity Consideration, each party releases and forever discharges the other party and its foregoing related persons from any and all claim…

Text removed vs the prior filing · source: 10-Q · 2025-08-19

• During the six months ended June 30, 2025, none of our directors or officers adopted, terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K of the Exchange Act.